|
CN105294761A
|
|
Impurities of tenofovir disoproxil fumarate or tenofovir, and preparation method thereof
|
|
CN105272852A
|
|
Ezetimibe intermediate and preparation method
|
|
CN104276991A
|
|
Preparation method of pyrrolidine 2-carboxylate derivatives
|
|
CN104926704A
|
|
Nitrogen heterocyclic propane compound and preparation method thereof
|
|
CN104098481A
|
|
Preparation method of saxagliptin intermediate
|
|
CN104098556A
|
|
Novel synthetic process for rivaroxaban
|
|
CN104098544A
|
|
Preparation method of vandetanib
|
|
CN103992307A
|
|
Preparation method for crizotinib
|
|
CN103896700A
|
|
Preparation method of ezetimibe chiral intermediate
|
|
CN103420886A
|
|
Synthesis method of (3R,4R)-4-acetoxy-3-[(R)-1-(tert-butyldimethylsilyloxy)ethyl]azetidin-2-one related material
|
|
CN103420908A
|
|
Preparation method of montelukast chiral intermediate
|
|
CN103373941A
|
|
Preparation method of retigabine and intermediate thereof
|
|
CN103319311A
|
|
Preparation method of crizotinib intermediate (1S)-1-(2, 6-dichloro-3-fluorophenyl)ethanol
|
|
CN103193679A
|
|
Preparation method of rivastigmine intermediate (R)-N-ethyl-N-methyl carbamic acid-3-(1-hydroxyethyl) phenyl ester
|
|
CN103193600A
|
|
Method for preparing rivastigmine intermediate
|
|
CN102908331A
|
|
Duloxetine hydrochloride enteric capsules and preparation method thereof
|
|
CN102614140A
|
|
Iloperidone oral disintegrating tablet and its preparation method
|
|
CN102533888A
|
|
Continuous enzymatic method for producing L-tert-leucine
|
|
CN102465159A
|
|
Synthesis process for preparing eslicarbazepine with microbial method
|
|
CN102462679A
|
|
Iloperidone medicinal oral preparation and preparation method thereof
|
